Liver Disease – DHR Health Institute for Research & Development

Trial Category: Liver Disease

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non alcoholic Fatty Liver Disease (NAFLD) (MAESTRO NAFLD-1)

View Details →

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)

View Details →

Cohort Analysis of Non-alcoholic Fatty Liver Disease and Associated Diagnostic Performance of FibroScan

View Details →

A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis

View Details →

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AKR-001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

View Details →

A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

View Details →

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

View Details →

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

View Details →

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

View Details →

A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

View Details →